Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR 
Moderna to Present at Upcoming Conferences in November 2024
CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming...
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE...
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
Digital Marketing Initiatives to Highlight Innovative Non-Invasive Drug Screening Technology and Market Expansion PlansNEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE)...
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ETAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc....
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies;...
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary...
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel...
Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer
Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,...
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer
Accomplished Finance and Commercial Leader Brings Extensive Life Sciences ExpertiseCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc....
New Treatments, Novel Research Drive Better Survival Rates for Canadians with Lung Cancer, Offering Hope to Thousands: Lung Health Foundation
Lung Cancer Awareness Month: Survivors Share Stories of Hope and Resilience Amid Revolutionary Medical BreakthroughsTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE)...
Edesa Biotech’s Founder Makes Strategic Investment in the Company
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics...
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
Special Meeting of Stockholders Adjourned Due to Lack of QuorumSAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc....
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling...
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary...
MaxCyte to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
Hisense named first Official Partner of the FIFA Club World Cup 2025™
DUBAI, UAE, Oct. 31, 2024 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, announced it has...
Global Times: China’s AI tech brings more convenient, dignified life to people with disabilities and their families
BEIJING, Oct. 31, 2024 /PRNewswire/ -- When Yong Yong (pseudonym) navigates through the bustling exhibition hall, a soothing voice whisperers in...